RT Journal Article
SR Electronic
T1 Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.07.22270020
DO 10.1101/2022.02.07.22270020
A1 Massari, Marco
A1 Spila-Alegiani, Stefania
A1 Morciano, Cristina
A1 Spuri, Matteo
A1 Marchione, Pasquale
A1 Felicetti, Patrizia
A1 Belleudi, Valeria
A1 Poggi, Francesca Romana
A1 Lazzeretti, Marco
A1 Ercolanoni, Michele
A1 Clagnan, Elena
A1 Bovo, Emanuela
A1 Trifirò, Gianluca
A1 Moretti, Ugo
A1 Monaco, Giuseppe
A1 Leone, Olivia
A1 Cas, Roberto Da
A1 Petronzelli, Fiorella
A1 Tartaglia, Loriana
A1 Mores, Nadia
A1 Zanoni, Giovanna
A1 Rossi, Paola
A1 Samez, Sarah
A1 Zappetti, Cristina
A1 Marra, Anna Rosa
A1 Menniti-Ippolito, Francesca
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270020.abstract
AB Objectives To investigate the association between SARS-CoV-2 mRNA vaccines, BNT162b2 and mRNA-1273, and myocarditis/pericarditis.Design Self-Controlled Case Series study (SCCS) using national data on COVID-19 vaccination and emergency care/hospital admissions.Setting Italian Regions (Lombardia, Friuli Venezia Giulia, Veneto, Lazio).Participants 2,861,809 individuals, aged 12-39 years, vaccinated with the first doses of mRNA vaccines (2,405,759 BNT162b2 and 456,050 mRNA-1273) between 27 December 2020 and 30 September 2021.Main outcome measures First diagnosis of myocarditis/pericarditis within the study period. The incidence of events in the exposure risk periods (0-21 days from the vaccination day, subdivided in three equal intervals) for first and second dose was compared with baseline period. The SCCS model was fitted using conditional Poisson regression to estimate Relative Incidences (RI) and Excess of Cases (EC) per 100,000 vaccinated by dose, age, gender and brand.Results During the study period, 441 participants aged 12-39 years developed myocarditis/pericarditis (346 BNT162b2 and 95 mRNA-1273). During the 21-day risk interval there were 114 cases of myocarditis/pericarditis (74 BNT162b2 and 40 mRNA-1273) corresponding to a RI of 1.27 (0.87-1.85) and 2.16 (1.50-3.10) after first and second dose, respectively.An increased risk of myocarditis/pericarditis at [0-7) days was observed after first [RI=6.55; 95% Confidence Interval (2.73-15.72); EC per 100,000 vaccinated=2.0 (1.5-2.3)] and second dose [RI=7.59 (3.26-17.65); EC=5.5 (4.4-5.9)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.39 (2.02-5.68); EC=0.8 (0.6-1.0)]. In males, an increased risk at [0-7) days was observed after first [RI=12.28, 4.09-36.83; EC=3.8 (3.1-4.0)] and second dose [RI=11.91 (3.88-36.53); EC=8.8 (7.2-9.4)] of mRNA-1273 and after second dose of BNT162b2 [RI=3.45 (1.78-6.68); EC=1.0 (0.6-1.2)]. In females, an increased risk at [0-7) days was observed after second dose of BNT162b2 [RI=3.38 (1.47-7.74); EC=0.7 (0.3-0.9)]. At [0-7) days an increased risk following second dose of BNT162b2 was observed in the 12-17 years old [RI=5.74, (1.52-21.72); EC=1.7 (0.7-1.9)] and in 18-29 years old [RI=4.02 (1.81-8.91); EC=1.1 (0.6-1.3)]. At [0-7) days an increased risk after first [RI=7.58 (2.62-21.94); EC=3.5 (2.4-3.8)] and second [RI=9.58 (3.32-27.58); EC=8.3 (6.7-9.2)] dose of mRNA-1273 was found in 18-29 years old and after first dose in 30-39 years old [RI=6.57 (1.32-32.63); EC=1.0 (0.3-1.1)].Conclusions This population-based study indicates that mRNA vaccines were associated with myocarditis/pericarditis in the population younger than 40 years, whereas no association was observed in older subjects. The risk increased after the second dose and in the youngest for both vaccines, remained moderate following vaccination with BNT162b2, while was higher in males following vaccination with mRNA-1273. The public health implication of these findings should be weighed in the light of the overall efficacy and safety profile of both vaccines.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form. MM, SSA, CM, MS, PM, PF, VB, FRP, ML, ME, EC, EB, UM, GM, OL, RDC, FP, LT, NM, GZ, PR, SS, CZ, ARM, FMI have no conflicts of interest to disclose. GT reports grants from Kiora Kirin, Chiesi, Daiichi Sankyo and participation on a Data Safety Monitoring Board or Advisory Board of Eli Lilly, Amgen, Sanofi, SOBI, Gilead, PTC Therapeutics, ABBvie, Verpora and Daiichi Sankio.Funding StatementThis study received funding from Italian Medicine Agency (AIFA) in the framework of the collaboration agreement Efficacia real world e sicurezza dei vaccini anti Covid-19: studio di coorte e Self-Controlled Case Series (Effectiveness and safety of COVID-19 vaccines: cohort and Self-Controlled Case Series studies).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the National Unique Ethics Committee for the evaluation of clinical trials of medicines for human use and medical devices for patients with COVID 19 of the National Institute for Infectious Diseases Lazzaro Spallanzani in Rome (n. 335, 17/05/2021 and n. 399, 02/09/2021)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to regional and national data privacy regulations, individual-level data cannot be shared openly. Aggregated or jittered data will be shared on reasonable request to the corresponding author (CM).